CDK2 and breast carcinoma: The CDK2 inhibitor INX-315 induces cell cycle arrest and therapy-induced senescence, thereby controlling the growth of CCNE1-amplified cancers and CDK4/6 inhibitor-resistant breast cancers, which together supports future clinical development.